Showing results (51-60 of 78) with videos related to
Sort By:
Pageof 8
Clinical Genitourinary Cancer|January 6, 2015
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSFRahul R Aggarwal, Tomasz M Beer, Vivian K Weinberg, et al.Oncotarget|October 27, 2017
Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancerJennifer Podolak, Kristi Eilers, Timothy Newby, et al.European Urology|December 17, 2021
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTANFred Saad, Eric J Small, Felix Y Feng, et al.Investigational New Drugs|November 29, 2014
A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancerJoshi J Alumkal, Rachel Slottke, Jacob Schwartzman, et al.Urologic Oncology|November 10, 2019
Real-world practice patterns in veterans with metastatic castration-resistant prostate cancerAhmad S Halwani, Kelli M Rasmussen, Vikas Patil, et al.The Lancet. Oncology|September 15, 2018
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trialFred Saad, David Cella, Ethan Basch, et al.European Urology Focus|September 4, 2021
Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation TherapyStéphane Oudard, Boris Hadaschik, Fred Saad, et al.Nature|March 24, 2022
Androgen receptor activity in T cells limits checkpoint blockade efficacyXiangnan Guan, Fanny Polesso, Chaojie Wang, et al.Journal for Immunotherapy of Cancer|July 4, 2020
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide aloneJulie N Graff, Tomasz M Beer, Joshi J Alumkal, et al.JCO Precision Oncology|October 26, 2019
Molecular Testing in Patients With Castration-Resistant Prostate Cancer and Its Impact on Clinical Decision MakingDerrick L Tao, Shawna Bailey, Tomasz M Beer, et al.Pageof 8